The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma

참고문헌 (10)

1. Lee MMP, "The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma", J Liver Cancer, 23, pp.262~271 (2023)
2. "Guidelines" (2023)[URL]
3. Korean Liver Cancer Association(KLCA)and National Cancer Center(NCC)Korea, "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clin Mol Hepatol, 28, pp.583~705 (2022)
4. Bruix J, "Systemic treatment of hepatocellular carcinoma : An EASL position paper", J Hepatol, 75, pp.960~974 (2021)
5. Han S, "Sorafenib for 9, 923 patients with hepatocellular carcinoma : an analysis from National Health Insurance Claim Data in South Korea", Gut Liver, 18, pp.116~124 (2024)
6. Iavarone M, "Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib", Hepatology, 62, pp.784~791 (2015)
7. Goh MJ, "Clinical practice guideline and real-life practice in hepatocellular carcinoma : a Korean perspective", Clin Mol Hepatol, 29, pp.197~205 (2023)
8. Chan LL, "The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment", Clin Mol Hepatol, 29, pp.909~923 (2023)
9. Yoo C, "Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma : a multinational multicenter retrospective study", Liver Cancer, 10, pp.107~114 (2021)
10. Peng TR, "Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma", Int Immunopharmacol, 112, pp.109223~ (2022)

관련 논문AI추천